Reduction of Pro-Inflammatory Cytokines through Hemodiafiltration

REFERENCES

• Nolan CR. Strategies for improving long-term survival in patients with ESRD. J Am Soc Nephrol. 2005; 16(Suppl. 2)S120–S127
   Google Scholar
• Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med. 1999; 340: 115–126
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–874
   Google Scholar
• Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant. 2001; 16: 36–40
   Google Scholar
• Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648–658
   Google Scholar
• Ozeren A, Aydin M, Tokac M, Demircan N, Unalacak M, Gurel A, Yazici M. Levels of serum IL-1beta, IL-2, IL-8 and tumor necrosis factor-alpha in patients with unstable angina pectoris. Mediators Inflamm. 2003; 12: 361–365
   Google Scholar
• Nakanishi I, Moutabarrik A, Okada N, Kitamura E, Hayashi A, Syouji T, Namiki M, Ishibashi M, Zaid D, Tsubakihara Y. Interleukin-8 in chronic renal failure and dialysis patients. Nephrol Dial Transplant. 1994; 9: 1435–1442
   Google Scholar
• Herbelin A, Ureña P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int. 1991; 39: 954–960
   Google Scholar
• Borazan A, Ustün H, Ustundag Y, Aydemir S, Bayraktaroglu T, Sert M, Yilmaz A. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels. Mediators Inflamm. 2004; 13: 201–204
   PubMed Web of Science ®Google Scholar
• Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH. Immunologic function and survival in hemodialysis patients. Kidney Int. 1998; 54: 236–244
   PubMed Web of Science ®Google Scholar
• Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med. 1993; 21: 522–526
   PubMed Web of Science ®Google Scholar
• Morgera S, Slowinski T, Melzer C, Sobottke V, Vargas-Hein O, Volk T, Zuckermann-Becker H, Wegner B, Müller JM, Baumann G, Kox WJ, Bellomo R, Neumayer HH. Renal replacement therapy with high-cutoff hemofilters: Impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis. 2004; 43: 444–453
   PubMed Web of Science ®Google Scholar
• Morgera S, Klonower D, Rocktäschel J, Haase M, Priem F, Ziemer S, Wegner B, Göhl H, Neumayer HH. TNF-alpha elimination with high cut-off hemofilters: A feasible clinical modality for septic patients?. Nephrol Dial Transplant 2003; 18: 1361–1369
   Google Scholar
• Sargent J. Control of dialysis by a single-pool urea model. The National Cooperative Dialysis Study. Kidney Int. 1983; 23(Suppl. 13)S19–S25
   Google Scholar
• Daugirdas JT. The post:pre-dialysis plasma urea nitrogen ratio to estimate Kt/V and nPCR: Mathematic modelling and validation. Int J Artif Organs. 1989; 12: 411–419
   PubMed Web of Science ®Google Scholar
• Vidt DG. Inflammation in renal disease. Am J Cardiol 2006; 97: 20A–27A
   PubMed Web of Science ®Google Scholar
• Yuen D, Chan CT. Inflammation, cardiovascular disease and nocturnal hemodialysis. Curr Opin Nephrol Hypertens 2005; 14: 538–542
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Sylvestre LC, Stenvinkel P. Chronic kidney disease and inflammation in pediatric patients: From bench to playground. Pediatr Nephrol. 2005; 20: 714–720
   PubMed Web of Science ®Google Scholar
• Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS. Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1998; 18: 387–394
   PubMed Web of Science ®Google Scholar
• Jialal I, Devaraj S, Venugopal SK. C-reactive protein: Risk marker or mediator in atherothrombosis?. Hypertension 2004; 44: 6–11
   PubMed Web of Science ®Google Scholar
• Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int. 2002; 62: 1417–1422
   PubMed Web of Science ®Google Scholar
• Lotz M. Interleukin-6. Cancer Invest. 1993; 11: 732–742
   PubMed Web of Science ®Google Scholar
• Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996; 127: 263–271
   PubMed Web of Science ®Google Scholar
• Ghani RA, Zainudin S, Ctkong N, Rahman AF, Wafa SR, Mohamad M, Manaf MR, Ismail R. Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume hemofiltration and continuous venovenous hemofiltration. Nephrology (Carlton) 2006; 11: 386–393
   PubMed Web of Science ®Google Scholar
• Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990; 65: 297–302
   PubMed Web of Science ®Google Scholar
• Maury CPJ, Teppo AM. Circulating tumor necrosis factor-α (cachectin) in myocardial infarction. J Int Med. 1989; 225: 333–336
   PubMedGoogle Scholar
• Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74–80
   PubMedGoogle Scholar
• van Bommel EF, Hesse CJ, Jutte NH, Zietse R, Bruining HA, Weimar W. Cytokine kinetics (TNF-alpha, IL-1 beta, IL-6) during continuous hemofiltration: A laboratory and clinical study. Contrib Nephrol. 1995; 116: 62–75
   PubMedGoogle Scholar
• Lonnemann G, Bechstein M, Linnenweber S, Burg M, Koch KM. Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure. Kidney Int Suppl. 1999; 72: S84–S87
   Google Scholar
• Matsumoto S, Tsuji-Takayama K, Aizawa Y, Koide K, Takeuchi M, Ohta T, Kurimoto M. Interleukin-18 activates NF-kappaB in murine T helper type 1 cells. Biochem Biophys Res Commun. 1997; 234: 454–457
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836–843
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ, Investigators AtheroGene. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002; 106: 24–30
   PubMed Web of Science ®Google Scholar
• Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, Chvatchko Y, Tedgui A. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 2002; 88: 467–469
   PubMed Web of Science ®Google Scholar
• Gangemi S, Mallamace A, Minciullo PL, Santoro D, Merendino RA, Savica V, Bellinghieri G. Involvement of interleukin-18 in patients on maintenance hemodialysis. Am J Nephrol. 2002; 22: 417–421
   PubMed Web of Science ®Google Scholar
• Uchimura T, Motomiya Y, Okamura H, Hashiguchi T, Miura M, Uji Y, Iwamoto H, Maruyama I. Marked increases in macrophage colony-stimulating factor and interleukin-18 in maintenance hemodialysis patients: Comparative study of advanced glycation end products, carboxymethyllysine and pentosidine. Nephron. 2002; 90: 401–407
   Google Scholar
• Sahar S, Dwarakanath RS, Reddy MA, Lanting L, Todorov I, Natarajan R. Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: A novel cross-talk in the pathogenesis of atherosclerosis. Circ Res. 2005; 96: 1064–1071
   Google Scholar
• Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001; 104: 1598–1603
   PubMed Web of Science ®Google Scholar
• Martins TB, Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Roberts WL, Carlquist JF. Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. Am J Clin Pathol. 2006; 125: 906–913
   PubMed Web of Science ®Google Scholar
• Tenger C, Sundborger A, Jawien J, Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol. 2005; 25: 791–796
   Google Scholar
• Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res. 2001; 89: E41–E45
   PubMed Web of Science ®Google Scholar
• Schindler R. Inflammation and dialysate quality. Hemodial Int. 2006; 10(Suppl. 1)S56–S59
   Google Scholar
• Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 2001; 16: 1863–1869
   PubMed Web of Science ®Google Scholar
• Unruh M, Benz R, Greene T, Yan G, Beddhu S, DeVita M, Dwyer JT, Kimmel PL, Kusek JW, Martin A, Rehm-McGillicuddy J, Teehan BP, Meyer KB. HEMO Study Group. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int. 2004; 66: 355–366
   PubMed Web of Science ®Google Scholar
• Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, Klassen P, Port FK. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int. 2006; 69: 2087–2093
   PubMed Web of Science ®Google Scholar